

MARKET REPORT



Ulcerative colitis- Pipeline Review, 2019

BioPortfolio

Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Ulcerative colitis- Pipeline Review, 2019

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Ulcerative colitis- Pipeline Review, 2019

FirstView Market Insight "Ulcerative Colitis- Pipeline Review, 2019" provides an overview of the pipeline landscape for Ulcerative Colitis- Pipeline Review, 2019. It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc. These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.

Ulcerative colitis (UC) is a disease of colon or large intestine, which leads to inflammation of the colon and development of tiny sores that produce mucous or pus. The disease happens due to dysfunction of immune system. As a result of the response, white blood cells (WBCs) start reaching the large intestine lining, causing inflammation of the colon. Symptoms of the disease include loose or urgent bowel movements, abdominal cramps, bloody stools, and others. Family history is one of the significant risk factors for UC. The disease is non-contagious, whereas the exact reason of the disease is unknown.

There are many treatment options available such as Antibiotics, Aminosalicylates (5-ASAs), Corticosteroids, Immunomodulators, Biologics, other oral agents. Conventional therapies (aminosalicylates, corticosteroids, immunosuppressants) are the first line therapies for the treatment of ulcerative colitis. TNF- α inhibitors remains the mainstream biological therapies for the treatment of Ulcerative colitis. Remicade and Humira remains the major therapies indicated for the treatment of ulcerative colitis. Xeljanz recently got approval from US FDA with a novel mechanism of action has advantage in its oral route of administration. Gilead/Galapagos's filgotinib and AbbVie's upadacitinib are other drugs which are expected to enter the market soon and have great credentials to pose a threat to the existing therapies.

Ulcerative colitis (UC) is the most common form of inflammatory bowel disease which affects several people. From a global perspective, several research studies in 2018 have reported annual incidence rates of UC ranging from 0.5 to 24.5 cases per 100,000 people. On the other hand, incidences have been increasing in Asian and South European countries. In the United States, UC affects an estimated 500,000 people and is the cause of 250,000 doctor visits and 30,000 hospitalizations, each year. UC has an uneven presence in major geographical regions across the world. The ulcerative colitis market was valued at USD 6,854.47 million in 2018, and is also expected to register a CAGR of 4.86% during the forecast period (2019-2029).

Ulcerative Proctitis Segment is Expected to Experience the Fastest Growth during the Forecast Period

Ulcerative proctitis is one of the types of ulcerative colitis. It is considered as the initial manifestation of ulcerative colitis, in which fine ulcerations in the inner linings of mucosa of the large intestine are seen. A survey was conducted by NIH in 2016, to understand the prevalence of disease, which gave results, such as 25% of the pediatric patients surveyed had the disease, and 17 to 21% of the adult patients had ulcerative proctitis. As per this data obtained by the survey, NIH stated that there was a rise in the number of patients suffering from ulcerative proctitis, compared to the previous years. Hence, this segment, by disease type, is believed to experience growth in the future.

Report Overview:

This part of report provides detailed description of indication which enables the client to understand the landscape of the Ulcerative colitis disease. This report covers the basic definition, etiology, symptoms, disease progression, treatment guidelines, pathophysiology, methods to diagnose for Ulcerative colitis disease.

Pipeline Overview:

This report provides extensive scenario and growth prospects of the market. This section includes the graphical representations of the future treatment landscape based on various phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. It also includes details of products

which have been dormant or discontinued during the trial stages of development.

Drug Profile Overview:

The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.

Clinical Trial Overview:

This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.

Product Development Activity:

This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.

Company Overview:

Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial

Scope

- The report provides a competitive landscape of Ulcerative colitis
- The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status
- The report provides the list of companies which are the most active in the pipeline
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery
- The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities
- The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)
- The report summarizes all the dormant and discontinued pipeline projects
- The report also provides latest news for the past one year

Reasons To Buy

- To identifying prominent players in the Ulcerative colitis treatment landscape
- To determine the drivers; barriers and unmet need in the Ulcerative colitis treatment space
- Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies
- Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration

Additional Details

Publisher : First View Insight

Reference :

Number of Pages : 146

Report Format : PDF

Publisher Information :



Our systems go beyond providing extensive comprehensive studies. We inspire our clients to develop knowledgeable growth mechanisms. Our insights are precise and approved by peer-driven research methodology. In brief, we pay emphasis on the success stories of our clients. When assessing solutions, we focus entirely on enabling them to influence their true potential for growth.

About FirstView Insight

FirstView Insight is a global market research and business consulting firm which focuses exclusively on healthcare domain. We help pharmaceutical companies to turn out to be progressively focused in a rapidly evolving market characterized by unpredictable product pipelines and uncertain regulatory actions.

Table Of Contents for Ulcerative colitis- Pipeline Review, 2019

- 1. Disease overview
 - 1.1. Pathophysiology
 - 1.2. Symptoms
 - 1.3. Etiology
 - 1.4. Diagnosis
 - 1.5. Etiology
 - 1.6. Treatment Algorithm
 - 1.7. Treatment Options
- 2. Featured News and Press Releases, 2018-2019
- 3. List of companies developing Ulcerative Colitis- Pipeline Review, 2019
- 4. Treatment Algorithm
 - 4.1. Drug classes
 - 4.1.1. TNF-Alpha Inhibitor
 - 4.1.2. Cell Adhesion Molecule Inhibitors
 - 4.1.3. Janus-Activated Kinase Inhibitors
 - 4.1.4. Sphingosine--Phosphate Receptor Modulators
 - 4.1.5. Aminosalicylates
 - 4.1.6. Corticosteroids
 - 4.1.7. Immunosuppressants
- 5. Current Unmet Needs
- 6. Market Trnd:
- 7. Pipeline Therapeutics
- 8. Therapeutics under Development by Companies
- 9. Late Stage Products (Phase III)
 - 9.1. Alicaforsen (ICAM-1) Ionis/Atlantic
 - 9.1.1. Product Description
 - 9.1.2. Research and Development
 - 9.1.3. Product Development Activities
 - 9.2. AJM 300 (alpha4 integrin receptor antagonist)
 - 9.2.1. Product Description
 - 9.2.2. Research and Development
 - 9.2.3. Product Development Activities
 - 9.3. Entyvio SC (anti- $\alpha 4\beta 7$ integrin)
 - 9.3.1. Product Description
 - 9.3.2. Research and Development
 - 9.3.3. Product Development Activities
 - 9.4. Etrolizumab (RG7413, anti- $\alpha 4\beta 7 / \alpha E\beta 7$)
 - 9.4.1. Product Description
 - 9.4.2. Research and Development
 - 9.4.3. Product Development Activities
 - 9.5. Filgotinib (GLPG0634; JAK1)
 - 9.5.1. Product Description
 - 9.5.2. Research and Development
 - 9.5.3. Product Development Activities
 - 9.6. Ozanimod (RPC1063; S1PR1)
 - 9.6.1. Product Description
 - 9.6.2. Research and Development
 - 9.6.3. Product Development Activities
- 10. Mid Stage Products (Phase II)
 - 10.1. ABI464 (RNA biogenesis)
 - 10.1.1. Product Description
 - 10.1.2. Research and Development
 - 10.1.3. Product Development Activities
 - 10.2. Bimekizumab (UCB-4940; anti-IL-17AF)
 - 10.2.1. Product Description
 - 10.2.2. Research and Development
 - 10.2.3. Product Development Activities
 - 10.3. Brilacidin (antibiotic)
 - 10.3.1. Product Description
 - 10.3.2. Research and Development
 - 10.3.3. Product Development Activities
 - 10.4. DW200710
 - 10.4.1. Product Description
 - 10.4.2. Research and Development
 - 10.4.3. Product Development Activities
 - 10.5. E6007 (integrin)
 - 10.5.1. Product Description
 - 10.5.2. Research and Development
 - 10.5.3. Product Development Activities
 - 10.6. Etrasimod (APD334; S1PR1)
 - 10.6.1. Product Description
 - 10.6.2. Research and Development
 - 10.6.3. Product Development Activities
 - 10.7. INN-108
 - 10.7.1. Product Description
 - 10.7.2. Research and Development
 - 10.7.3. Product Development Activities
 - 10.8. Kappaproct (DIMS 0150; NF-kappa B inhibitor, rectal admin)
 - 10.8.1. Product Description
 - 10.8.2. Research and Development
 - 10.8.3. Product Development Activities
 - 10.9. KHK4083 (anti-OX40)
 - 10.9.1. Product Description
 - 10.9.2. Research and Development
 - 10.9.3. Product Development Activities
 - 10.10. OPRX-106 (TNF α)
 - 10.10.1. Product Description
 - 10.10.2. Research and Development
 - 10.10.3. Product Development Activities
 - 10.11. PF-06480605 (anti-TL1A)
 - 10.11.1. Product Description
 - 10.11.2. Research and Development
 - 10.11.3. Product Development Activities
 - 10.12. PF-06651600 (JAK3)
 - 10.12.1. Product Description
 - 10.12.2. Research and Development
 - 10.12.3. Product Development Activities
 - 10.13. Otezla (PDE4)
 - 10.13.1. Product Description
 - 10.13.2. Research and Development
 - 10.13.3. Product Development Activities
- 11. Early Stage Products (Phase I and IND)
 - 11.1. Bepecin (pentadecapeptide)
 - 11.1.1. Product Description
 - 11.1.2. Research and Development
 - 11.1.3. Product Development Activities
 - 11.2. BMS-986184 (anti-CSCL10 / IP10)
 - 11.2.1. Product Description
 - 11.2.2. Research and Development
 - 11.2.3. Product Development Activities
 - 11.3. Dolcanatide (SP 333; guanylate cyclase-C agonist)
 - 11.3.1. Product Description
 - 11.3.2. Research and Development
 - 11.3.3. Product Development Activities
 - 11.4. KAG-308 (prostaglandin-E-EP4 receptor agonist)
 - 11.4.1. Product Description
 - 11.4.2. Research and Development
 - 11.4.3. Product Development Activities
 - 11.5. RG 7880 (anti-IL-22)
 - 11.5.1. Product Description
 - 11.5.2. Research and Development
 - 11.5.3. Product Development Activities
 - 11.6. TD-1473 (GI-targeted pan-JAK)
 - 11.6.1. Product Description
 - 11.6.2. Research and Development
 - 11.6.3. Product Development Activities
 - 11.7. AVX-740 (oral TNF)
 - 11.7.1. Product Description
 - 11.7.2. Research and Development
 - 11.7.3. Product Development Activities
 - 11.8. GSK 2245840 (SRT 2104, SIRT1 activator)
 - 11.8.1. Product Description
 - 11.8.2. Research and Development
 - 11.8.3. Product Development Activities
- 12. Pre-Clinical and Discovery Products
 - 12.1. LY 3207447
 - 12.1.1. Product Description
 - 12.1.2. Research and Development
 - 12.1.3. Product Development Activities
 - 12.2. ABP 20112
 - 12.2.1. Product Description
 - 12.2.2. Research and Development
 - 12.2.3. Product Development Activities
- 13. Drivers of Ulcerative Colitis - Pipeline Review, 2019
- 14. Constraints of Ulcerative Colitis Pipeline Review, 2019
- 15. Therapeutic Assessment
 - 15.1. Assessment by Route of Administration
 - 15.2. Assessment by Phase & Route of Administration
 - 15.3. Assessment by Molecule Type
 - 15.4. Assessment by Phase & Molecule type
 - 15.5. Assessment by Target
 - 15.6. Assessment by Mechanism of Action
- 16. Collaborations and Acquisitions Details
- 17. Dormant Products
- 18. Discontinued Products
- 19. Market Trends
- 20. Market Opportunity Assessment
- 21. Unmet Needs
- 22. SWOT Analysis
- 23. Appendix
- 24. Report Methodology
- 25. Consulting Services
- 26. Disclaimer

List Of Tables in Ulcerative colitis- Pipeline Review, 2019

Table 1: Marketed and Pipeline Ulcerative Colitis- Pipeline Review, 2019 drugs, 2019

Table 2: Sales of Marketed drugs, 2019

Table 3: Patent expiration details - marketed drugs, 2019

Table 4: Number of Products Under Development for Ulcerative Colitis- Pipeline Review, 2019, 2019

Table 5: Products under Development by Companies, 2019

Table 6: Late Stage Products, 2019

Table 7: Mid Stage Products, 2019

Table 8: Early Stage Products, 2019

Table 9: Pre-Clinical and Discovery Products, 2019

Table 10: Assessment by Route of Administration, 2019

Table 11: Assessment by Stage and Route of Administration, 2019

Table 12: Assessment by Molecule Type, 2019

Table 13: Assessment by Stage and Molecule Type, 2019

Table 14: Assessment by Target, 2019

Table 15: Assessment by Mechanism of Action, 2019

Table 16: Dormant Products, 2019

Table 17: Discontinued Products, 2019

List Of Figures, Charts and Diagrams in Ulcerative colitis- Pipeline Review, 2019

Figure 1: Marketed and Pipeline Ulcerative Colitis- Pipeline Review, 2019 drugs, 2019

Figure 2: Sales of Marketed drugs, 2019

Figure 3: Patent expiration details – marketed drugs, 2019

Figure 4: Number of Products Under Development for Ulcerative Colitis- Pipeline Review, 2019, 2019

Figure 5: Products under Development by Companies, 2019

Figure 6: Late Stage Products, 2019

Figure 7: Mid Stage Products, 2019

Figure 8: Early Stage Products, 2019

Figure 9: Pre-Clinical and Discovery Products, 2019

Figure 10: Assessment by Route of Administration, 2019

Figure 11: Assessment by Stage and Route of Administration, 2019

Figure 12: Assessment by Molecule Type, 2019

Figure 13: Assessment by Stage and Molecule Type, 2019

Figure 14: Assessment by Target, 2019

Figure 15: Assessment by Mechanism of Action, 2019

Figure 16: Dormant Products, 2019

Figure 17: Discontinued Products, 2019

How to Buy...

Ulcerative colitis- Pipeline Review, 2019

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/238699>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$1063** | Single User Price
- \$1870** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.